Peptic Ulcer Drugs Market Size (2022-2030) worth US$ 5.38 Billion| To grow at a CAGR of 2.6%, Growth Plus Reports

Pune, Nov. 09, 2022 (GLOBE NEWSWIRE) — According to the latest report published by Growth Plus Reports, the global Peptic Ulcer Drugs Market is expected to clock US$ 5.38 billion by 2030 and to grow at a CAGR of 2.6% during the forecast period. This exclusive information is published by Growth Plus Reports in its report titled “Peptic Ulcer Drugs Market – Global Outlook & Forecast 2022-2030” This exclusive information is published by Growth Plus Reports in its report titled “peptic ulcer drugs Market – Global Outlook & Forecast 2022-2030”

Get a Sample Copy of the Research Report: https://growthplusreports.com/inquiry/request-sample/peptic-ulcer-drugs-market/7912

A peptic ulcer is a sore that develops in the stomach’s inner lining, causing damage to the stomach, esophagus, and duodenum. This disorder may be caused by the overuse of pain relievers or by the pathogenic bacteria Helicobacter pylori (H. pylori). This medical disease can progress to more significant issues, such as stomach holes and substantial damage to the stomach, the lower esophagus, and the upper duodenum. As a result, different medications are employed to treat such a problem to avoid such significant repercussions.

Market Drivers

The peptic ulcer drugs market is expanding rapidly and is expected to grow significantly during the forecast period. Such market expansion may be attributable to the increased frequency of peptic ulcers, the growing elderly population, and product innovations. Additionally, expanding R&D activity, solid product pipeline, and growing usage of triple treatment. Furthermore, increased government and corporate efforts, financing, and investments stimulate the growth of the peptic medication industry.

The global peptic ulcer drugs market has been analyzed from four perspectives: drug type, ulcer type, distribution channel, and region.

Excerpts from ‘By Ulcer Type Segmentation’

Based on the ulcer types, the global peptic ulcer drugs market has been segmented into:

• Duodenal Ulcers
• Esophageal Ulcers
• Gastric Ulcers

The market is dominated by duodenal ulcers, with the largest revenue share due to the high prevalence of duodenal ulcers and rising public awareness of novel treatments for it being one of the reasons for its prevalence. The risk factors for duodenal ulcers include heavy smoking, excessive alcohol use, high stress, a high intake of spicy and greasy foods, and many more, all of which increase the development of duodenal ulcers. Due to the rising frequency of stomach ulcers, gastric ulcers occupy the second biggest revenue share in the worldwide peptic ulcer medication market.

Inquiry Before Buying: https://growthplusreports.com/inquiry/before-buying/peptic-ulcer-drugs-market/7912

Excerpts from ‘By Region Segmentation’

The global peptic ulcer drugs market has been segmented into:

• North America
• Europe
• Asia Pacific
• Rest of the World

North America holds the largest revenue share in the market. Various factors, such as the high prevalence of peptic ulcers, a large base of the elderly population, and the advanced healthcare infrastructure, can be attributed to segment growth. The market in North America is expanding due to the high healthcare spending, rapid growth in R&D activities, and technological advancement. A broad base of market players and an increase in novel product approvals are also anticipated to boost the industry. Europe is the second-largest market participant due to its highly developed healthcare infrastructure and high healthcare expenditure.

Although the Asia Pacific is a developing region, it has a large aging population, a rapidly evolving healthcare industry, and an increasing usage of new technologies. The Asia Pacific peptic ulcer medication market is being pushed by increased medical tourism and healthcare expenditure for better medical facilities.

Excerpts from ‘Competitive Landscape’

The prominent players operating in the peptic ulcer drugs market are

• Pfizer Inc.
• Abbott Laboratories
• Takeda Pharmaceutical Company Limited
• AstraZeneca PLC
• GlaxoSmithKline plc.
• Novartis AG
• Mylan Pharmaceuticals Inc.
• Novitium Pharma LLC
• Eisai Co. Ltd.
• Yuhan Corporation
• Zydus Lifesciences Limited
• Boehringer Ingelheim

VALUE PROPOSITIONS RELATED TO THE REPORT:

• Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
• Comprehensive quantitative and qualitative insights at segment and sub-segment level
• Covid 19 impact trends and perspective
• Granular insights at global/regional/country level
• Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
• Blanket coverage on competitive landscape
• Winning imperatives
• Exhaustive coverage on ‘Strategic Developments’ registered by leading players of the market

CUSTOMIZATION OPTIONS:

• Distributor Landscape Assessment
• Pricing Intelligence
• Customer Base Assessment
• Investment & Initiatives Analysis
• ‘Business Profile’ of Key Players

Directly Purchase Premium Copy of Peptic Ulcer Drugs Market Growth Report (2022-2030) at: https://growthplusreports.com/checkout?_token=AdQKzvT3nUcFSQiimXTXBGtD1ovOfMGHqTPYktDA&report_id=7912&license=Single

About Us:

Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as “Most Innovative Healthcare Market Research Company in 2020.